Innovent Biologics Inc Asset Resilience Ratio

Latest as of December 2025: 2.37%

Innovent Biologics Inc asset resilience ratio. Innovent Biologics Inc (6IB) has an Asset Resilience Ratio of 2.37% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Innovent Biologics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€886.74 Million

≈ $1.04 Billion USD Cash + Short-term Investments

Total Assets

€37.35 Billion

≈ $43.66 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Innovent Biologics Inc (2016–2025)

Asset resilience ratio of Innovent Biologics Inc from 2016 to 2025. This chart shows how Innovent Biologics Inc's Asset Resilience Ratio has changed over time. Read 6IB total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Innovent Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Innovent Biologics Inc assets under control.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€886.74 Million	2.37%
Total Liquid Assets	€886.74 Million	2.37%

Asset Resilience Insights

Limited Liquidity: Innovent Biologics Inc maintains only 2.37% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Innovent Biologics Inc Industry Peers by Asset Resilience Ratio

Compare Innovent Biologics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Shanghai Medicilon Inc SHG:688202	Biotechnology	6.69%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.76%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%

Innovent Biologics Inc Asset Resilience Ratio by Year (2016–2025)

Innovent Biologics Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Innovent Biologics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.37%	€886.74 Million ≈ $1.04 Billion	€37.35 Billion ≈ $43.66 Billion	+0.64pp
2024-12-31	1.74%	€375.56 Million ≈ $439.06 Million	€21.60 Billion ≈ $25.26 Billion	-34.01pp
2023-12-31	35.75%	€7.37 Billion ≈ $8.62 Billion	€20.63 Billion ≈ $24.12 Billion	-5.46pp
2022-12-31	41.21%	€7.25 Billion ≈ $8.47 Billion	€17.59 Billion ≈ $20.56 Billion	+37.24pp
2021-12-31	3.97%	€644.85 Million ≈ $753.90 Million	€16.24 Billion ≈ $18.99 Billion	+0.95pp
2020-12-31	3.02%	€357.30 Million ≈ $417.72 Million	€11.83 Billion ≈ $13.84 Billion	-28.37pp
2019-12-31	31.39%	€2.27 Billion ≈ $2.65 Billion	€7.23 Billion ≈ $8.45 Billion	-1.56pp
2017-12-31	32.94%	€809.48 Million ≈ $946.37 Million	€2.46 Billion ≈ $2.87 Billion	+5.16pp
2016-12-31	27.78%	€782.25 Million ≈ $914.53 Million	€2.82 Billion ≈ $3.29 Billion	--

pp = percentage points

About Innovent Biologics Inc

F:6IB Germany Biotechnology

Market Cap

$18.64 Billion

€15.94 Billion EUR

Market Cap Rank

#1377 Global

#315 in Germany

Share Price

€9.16

Change (1 day)

-0.61%

52-Week Range

€7.96 - €11.96

All Time High

€11.96